Bahrain

Reimbursed Care Access

Bahrain maintains strict national controls on narcotics and psychotropic substances administered and enforced through the National Health Regulatory Authority (NHRA) and criminal law. Traditional psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are treated as controlled substances with no authorized medical use outside approved research; ketamine is available and used in medical settings as an anesthetic and for off‑label psychiatric use within regulated health facilities. There is no public, nation‑wide reimbursement program or NHRA‑published marketing approval (as of Feb 20, 2026) for branded intranasal esketamine (Spravato) in Bahrain’s publicly available regulatory records.